Universita' Politecnica Delle Marche
- Address
- lock Available on a paid plan
Immune System Diseases and Musculoskeletal Diseases
At Universita' Politecnica Delle Marche, clinical research in this area focuses on the overlap between immune system disorders and muscle-related conditions, with particular attention to polymyositis and dermatomyositis. The studies are designed to better understand disease activity and assess whether new treatment approaches can improve patient outcomes.
- Exploring treatment options for idiopathic inflammatory myopathies
- Evaluating the impact of anifrolumab compared with placebo alongside standard care
- Assessing improvement in disease activity for adults with polymyositis and dermatomyositis
This work reflects a focused effort in clinical immunology and rheumatology, aiming to support more effective care for people living with these rare inflammatory diseases.
Immune System Phenomena and Musculoskeletal and Neural Physiological Phenomena
The research portfolio also examines key immune system processes and their effects on muscle function and related physiological changes. Conducted at the Department of Molecular and Clinical Sciences, these trials contribute to a better understanding of how inflammation influences disease progression and treatment response.
- Studying immune-mediated inflammation in inflammatory myopathies
- Investigating how therapy may improve musculoskeletal symptoms
- Supporting research into more precise disease control for affected adults
With a small but targeted trial base and broad investigator involvement, the site is building knowledge around autoimmune muscle disease and practical ways to measure treatment benefit.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 24 therapeutic areas and 15 of 430 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 417 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 98 by active trials.
- 1Novartis Pharma AG11active
lock +97 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG22trials
lock +54 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universita' Politecnica Delle Marche
lock Showing 1 of 310 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 430 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 16 | Unknown | 2017-10-02 | 2025-09-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.